drugset / Trial / NCT00109291

Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease

NCT00109291

Phase 2 Terminated 17 enrolled Affymax
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.

Timeline

Start
2005-03
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject peginesatide Peptide 0.025 mg/kg Intravenous
Subject peginesatide Peptide 0.05 mg/kg Intravenous
Subject peginesatide Peptide 0.1 mg/kg Intravenous